Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →On December 19, 2025, Amicus Therapeutics, Inc. entered into an Agreement and Plan of Merger with BioMarin Pharmaceutical Inc. and a wholly-owned subsidiary,…
BioMarin's Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition. Leerink Partners analyst Joseph Schwartz: the acquisition of…
BioMarin quietly discards liver disease candidate after $4.8B Amicus announcement. Three days after announcing its largest-ever acquisition, BioMarin disclosed…
Source summaries from our enrichment pipeline; follow links for originals.
All 16 sources with sentiment breakdown →
BioMarin completed its acquisition of Amicus Therapeutics on April 27, 2026, for $14.50/share in cash, total equity value ~$4.8B (a 33% premium) - BioMarin's largest-ever transaction. The deal closed as a one-step all-cash merger after Amicus stockholders approved it and the final regulatory condition (France Ministry of Economics and Finance clearance, April 23, 2026) was satisfied; U.S. FTC granted HSR early termination on February 11, 2026. Amicus survives as a wholly owned BioMarin subsidiary and was delisted from Nasdaq. The acquisition strengthens BioMarin's rare disease portfolio with two commercial lysosomal storage disorder therapies - Galafold (migalastat) for Fabry disease and Pombiliti+Opfolda (cipaglucosidase alfa-atga + miglustat) for Pompe disease - plus the late-stage kidney asset DMX-200 (Phase 3, FSGS).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| BioMarin Pharmaceutical Inc. / Amicus Therapeutics, Inc. (this deal) | 2025 | $4.8B | — |
| BioMarin Pharmaceutical Inc. / Inozyme Pharma, Inc. | 2025 | $270M | — |
| Shire plc / Dyax Corp. | 2016 | $5.9B | 89 |
| Horizon Pharma plc / Hyperion Therapeutics, Inc. | 2015 | $1.1B | 79 |
| Shire plc / NPS Pharmaceuticals | 2015 | $5.2B | 78 |
| AstraZeneca PLC / Amolyt Pharma | 2024 | $1.1B | 73 |
| Sanofi SA / Inhibrx Inc. | 2024 | $2.2B | 70 |
← Browse all deals · How we score deals
More: 2025 deals · Rare Disease deals